This is a prospective, single-arm clinical study designed to evaluate the efficacy and safety of the BCMA/CD3 bispecific antibody (CM336) as maintenance therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
Be able to understand and voluntarily signs the informed consent form (ICF).
Age ≥ 18 years.
Newly diagnosed multiple myeloma according to the International Myeloma Working Group (IMWG) criteria.
MRD positivity (≥10-⁵) detected by EuroFlow.
Prior treatment with genetically modified adoptive cellular therapy.
History of allogeneic stem cell transplantation or solid organ transplantation.
Disease progression prior to enrollment (per IMWG 2016 response criteria), or presence of plasma cell leukemia, Waldenström macroglobulinemia, POEMS syndrome, or light-chain amyloidosis not attributable to symptomatic multiple myeloma.
Central nervous system involvement.